Overview
Gilead Sciences Poland operates in the biopharmaceutical sector, developing medicines and clinical programs in virology, oncology, and inflammation. The company is advancing investigational once-yearly lenacapavir and works to improve access to therapies and health equity.
Financials
Revenue history (in m)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2010-03-03. Active
44 1090 2851 0000 0001 3733 2501
37 1880 0009 0000 0011 0204 7000- 24 1090 2851 0000 0001 3733 2473
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Real estate
| Type | Amount |
|---|---|
Buildings and premises | PLN 44,367PLN 44,367 |
Public aid
No public aid cases recorded in the last 10 years.
Tenders
38 tenders recorded as contractor, with a total value of $399,449,259.
| Publication date | Subject | Amount | Contracting authority | |
|---|---|---|---|---|
| Sep 11, 2026 | Zakup i dostawa leków onkologicznych, preparatów do terapii car-t, immunoglobuliny dla apteki szpitalnej świętokrzyskiego centrum onkologii w kielcach | –– | Świętokrzyskie Centrum Onkologii Samodzielny Publiczny Zakład Opieki Zdrowotnej w Kielcach | |
| Aug 6, 2026 | DZP.242.281.2026 -Dostawa produktów leczniczych – Preparaty CAR-T [Axicabtagene ciloleucel, Lisocabtagene maraleucel] | $7.7M$7,663,274 | Uniwersytecki Szpital Kliniczny Im. Jana Mikulicza-Radeckiego We Wrocławiu | |
| Jul 2, 2026 | Dostawa leków stosowanych w programach lekowych. | $8.4M$8,350,389 | Centrum Onkologii Ziemi Lubelskiej Im. Św. Jana z Dukli |
Public sector contracts
Gilead Sciences Poland is the contractor in 4 public sector contracts, worth PLN 51.53m in total. They were signed with 4 public buyers.
| Public buyer | Value | |
|---|---|---|
| Uniwersyteckie Centrum Kliniczne | PLN 5,790,000 | |
| Uniwersytecki Szpital Kliniczny Im. Jana Mikulicza-Radeckiego we Wrocławiu | PLN 4,632,000 | |
| Świętokrzyskie Centrum Onkologii Samodzielny Publiczny Zakład Opieki Zdrowotnej w Kielcach | PLN 12,159,000 | |
| Dolnośląskie Centrum Onkologii, Pulmonologii I Hematologii | PLN 28,950,000 |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Authorized Representatives
Manner of representation
For representation, submitting declarations and signing on behalf of the company, each member of the management board is authorized to act independently.
Beneficial owners
| Person | Rights |
|---|---|
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Sanofisp. z o.o. | $384,123,246.36 | sanofi.com | ||
| MSD Polska Dystrybucjasp. z o.o. | $341,786,056.16 | msd.pl | ||
| Pfizer Trading Polskasp. z o.o. | $299,067,553.99 | pfizer.pl | ||
| Bristol-Myers Squibb Polskasp. z o.o. | $230,722,737.87 | bms.com | ||
| Takeda Pharmasp. z o.o. | $246,400,594.27 | takeda.com | ||
| Bialmedsp. z o.o. | $203,238,055.12 | bialmed.pl | ||
| Roche Diagnostics Polskasp. z o.o. | $199,208,461.57 | roche.pl | ||
| Servier Polska Servicessp. z o.o. | $157,143,144.15 | servier.pl | ||
| Zentiva Polskasp. z o.o. | $134,295,523.17 | zentiva.pl | ||
| Magnapharm Polandsp. z o.o. | $90,512,785.67 | magnapharm.pl |
Change history
| Date | Event | |
|---|---|---|
| 2015-11-04 | PKD change (Removed: 46.45.Z, 46.76.Z, 70.22.Z, 73.20.Z, 74.90.Z, 82.99.Z) | |
| 2010-10-19 | Address change (Postępu 15, 02-676, Warszawa → Postępu 17a, 02-676, Warszawa) | |
| 2010-09-24 | Address change (Al. Armii Ludowej 26, 00-609, Warszawa → Postępu 15, 02-676, Warszawa) | |
| 2010-03-08 | Entered in the register |
FAQ
Last updated: 2026-10-04